This inventor holds 8 USPTO granted patents and 22 published patent applications, plus 3 CIPO patents and 7 EPO patents. Top assignees: Prilenia Neurotherapeutics Ltd., The University of Texas System. Active years: 2020-2025.
Company Filing History:
8 out of 25 
2 out of 5,627 
Years Active: 2020-2025
Title: Michal Geva: Innovator in Neurotherapeutics
Introduction
Michal Geva is a talented inventor and researcher based in Even-Yehuda, Israel. With a prolific portfolio of eight patents, Michal has made significant contributions to the field of neurotherapeutics, particularly in treatments for Parkinson's Disease and related disorders.
Latest Patents
Among Michal Geva's most recent innovations are two notable patents. The first invention focuses on a method for treating Parkinsonism and its symptoms through the use of low-dose pridopidine. The second patent addresses the use of pridopidine for treating Rett syndrome, describing an effective method for administering this compound to afflicted individuals.
Career Highlights
Throughout his career, Michal has been associated with prominent organizations. Notably, he has worked at Prilenia Neurotherapeutics Ltd., where he contributed to the development of advanced therapeutic solutions. Additionally, his engagement with the University of Texas System has further enriched his expertise in neurotherapeutic research.
Collaborations
Michal Geva has collaborated with esteemed colleagues, including Michael Hayden and Ralph Laufer, who share a passion for advancing scientific knowledge and improving patient outcomes through innovative treatments.
Conclusion
With eight patents to his name, Michal Geva exemplifies the spirit of innovation in the medical field. His work continues to pave the way for new therapeutic options for individuals suffering from challenging neurological conditions. His contributions are invaluable in the ongoing search for effective treatments that can enhance the quality of life for many patients.